



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

## **GeneGo Releases MetaCore™ version 2.5**

### **A major release with 15 new features and significant increase in content**

St. Joseph, Michigan, May 2nd, 2005 - GeneGo Inc., a leading provider of databases, software and services in systems biology, announced today the release of a major new version of its flagship data mining suite MetaCore™ 2.5. The new version features fine mapping of human metabolism, transcription regulation and signaling; novel network building algorithms, filters and statistical procedures for multi-variant interpretation of human networks in terms of canonical pathways and functional processes. Primarily a human system, these tools are also applied for analysis of rat, mouse, fly, worm and yeast data.

“Over the past five years of development, we have undertaken for MetaCore™, we have always focused on the quality of the manually curated content and its utility for laboratory research; and these principles are emphasized in the new version,” said Dr. Tatiana Nikolskaya, Chief Scientific Officer, President and Founder of GeneGo. “First, we have completed the first fine mapping of human metabolism at the “sub-EC number” level of individual proteins (isozymes) and substrates. Second, we have resolved and networked virtually all human transcription factors and known receptors. Third, we have added novel network building algorithms and refined the existing ones. We have also developed a comprehensive toolkit for the statistical analysis of networks generated on the fly; including the evaluation and scoring of the relevance of networks to the experimental data, subcellular localization, canonical pathways and GO functional processes. Finally, we have added a large curated database of drugs, drug targets and diseases.”

"Over the last two years, MetaCore has become the platform of choice for functional analysis of genome scale experimental datasets in human and model organisms," said Julie Bryant, GeneGo's VP of business development. "In version 2.5, we have substantially expanded its content and capabilities in

interpretation of mammalian “interactome”. The current version is a mature third generation tool, whose features reflect numerous suggestions by our customers and collaborators in academy and industry. We also continue to maintain flexibility by integrating MetaCore with in house and third party algorithms as well as providing flexible business models for licensing.”

### **About GeneGo**

GeneGo is a Michigan-based company developing systems biology technology for life science research. The Company’s original computational platform allows the integration and analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, phenotypic data etc.) and relevant active chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo’s first product, MetaCore™, assists scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. GeneGo’s second product, MetaDrug™, is designed for medicinal chemists and enables prediction of metabolites and their likely toxicity in human.

For more information, please visit the company's Web site at [www.genego.com](http://www.genego.com) .

**MetaCore™, MetaDrug™ and MetaBase™** are trademarks of GeneGo, Inc